Determinants of Glycaemic Control in Children With Type 1 Diabetes - Trial NCT06325111
Access comprehensive clinical trial information for NCT06325111 through Pure Global AI's free database. This phase not specified trial is sponsored by IRCCS Burlo Garofolo and is currently Recruiting. The study focuses on Diabetes Mellitus, Type 1. Target enrollment is 800 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
IRCCS Burlo Garofolo
Timeline & Enrollment
N/A
May 29, 2023
Apr 30, 2026
Primary Outcome
Identification of genes involved in T1D glycaemic control,Identification of DNA methylation patterns involved in T1D glycaemic control,Identification of microRNAs involved in T1D glycaemic control,Identification of oral microbiome characteristics associated to T1D glycaemic control
Summary
Type 1 diabetes (T1D) is a common chronic disease of childhood associated with a
 significantly increased risk of micro- and macro-vascular complications, including
 neuropathy, nephropathy and cardiovascular diseases. The risk of development T1D
 comorbidities is associated with glycaemic control, a complex mechanism involving biological,
 physiological environmental factors.
 
 While more than 60 genetic variants were already associated with Glycated hemoglobin (HbA1c)
 in healthy subjects, very few genes have been identified in T1D individuals. Also,
 hyperglycaemia could be the cause of epigenetic changes at specific target genes, such as DNA
 methylation, histone modifications and microRNAs, correlated to accelerated development of
 diabetes-related complications. Most recently, increasing evidence also suggested that human
 microbiome may play a crucial role in the onset and progression of T1D and dysbiosis of the
 gut and oral microbiota was reported as a typical feature of hyperglycaemia.
 
 However, potential differences among poorly and good managed T1D subjects have not been still
 studied. Also, the exact mechanism by long-term hyperglycaemia's acts in T1D remains poorly
 understood. Therefore, this project will explore an emerging area of research by the study of
 possible genetic, epigenetic and environmental biomarkers among T1D subjects with different
 glycaemic control.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06325111
Non-Device Trial